Glipita M XR 50 mg+500 mg (Tablet (Extended Release))

Unit Price: ৳ 18.00 (3 x 10: ৳ 540.00)
Strip Price: ৳ 180.00

Medicine Details

Category Details
Generic Sitagliptin metformin hydrochloride
Company Beximco pharmaceuticals ltd
Also available as
Glipita m 50 mg tablet Glipita m 50 mg tablet Glipita m xr 50 mg tablet

Indications

  • Adjunct to diet and exercise for adults with type 2 diabetes mellitus
  • Improving glycemic control
  • Limitations of use in type 1 diabetes and diabetic ketoacidosis
  • Not studied in patients with a history of pancreatitis

Pharmacology

  • Combines sitagliptin and metformin HCl
  • Dipeptidyl peptidase-4 (DPP-4) inhibitor
  • Biguanide class mechanism of action
  • Inactivation of incretin hormones
  • Physiologic regulation of glucose homeostasis
  • Insulin synthesis and release
  • Glucagon secretion and hepatic glucose production

Dosage & Administration

  • Film-coated tablet
  • Individualized dosage
  • Maximum recommended daily dose
  • Gradual dose escalation
  • Twice daily with meals
  • Starting dose based on patient's current regimen
  • Extended-release tablet
  • Administer once daily with a meal
  • Adjusting dosing based on effectiveness and tolerability
  • Co-administration with insulin secretagogue or insulin

Interaction

  • Cationic drugs caution in renal tubular secretion
  • Phenprocoumon anticoagulant effect
  • Levothyroxine impact on hypoglycemic effect of metformin

Contraindications

  • Renal disease or dysfunction
  • Metabolic acidosis, including diabetic ketoacidosis
  • History of serious hypersensitivity reaction
  • Radiologic studies involving intravascular administration

Side Effects

  • Common adverse reactions
  • Hypoglycemia
  • Adverse reactions due to initiation of metformin therapy

Pregnancy & Lactation

  • Pregnancy Category B
  • Limited safety data in pregnant women
  • Excretion in human milk

Precautions & Warnings

  • Lactic Acidosis risk and symptoms
  • Thyroid-stimulating hormone (TSH) levels monitoring
  • Long-term association with vitamin B12 serum levels
  • Postmarketing reports of acute renal failure and pancreatitis
  • Hematologic parameters monitoring
  • Caution against excessive alcohol intake
  • Use during periods of stress and decreased fluid intake
  • Evaluation for evidence of ketoacidosis or lactic acidosis
  • Risk of hypoglycemia when used with insulin secretagogue or insulin
  • Postmarketing reports of serious allergic and hypersensitivity reactions
  • No clinical studies establishing conclusive evidence of macrovascular risk reduction

Overdose Effects

  • Sitagliptin overdose supportive measures
  • Modestly dialyzable sitagliptin
  • Metformin hydrochloride overdose and dialyzable clearance
  • Pancreatitis in the context of a metformin overdose

Therapeutic Class

  • Combination Oral hypoglycemic preparations

Storage Conditions

  • Store below 25°C
  • Dry place away from light
  • Safe place out of reach of children
  • Dispensed only on prescription

Related Brands